| Dr Salima Isabelle Hassanaly, MD, FRCSC | |
|
330 Brookline Ave, Boston, MA 02215-5400 | |
| (617) 667-3391 | |
| (312) 996-7770 |
| Full Name | Dr Salima Isabelle Hassanaly |
|---|---|
| Gender | Female |
| Speciality | Ophthalmology |
| Location | 330 Brookline Ave, Boston, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609304229 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207WX0120X | Ophthalmology - Cornea And External Diseases Specialist | 274516 (Massachusetts) | Secondary |
| 207W00000X | Ophthalmology | 274516 (Massachusetts) | Primary |
| Entity Name | The Board Of Trustees Of The University Of Illinois |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386863819 PECOS PAC ID: 3072422716 Enrollment ID: O20031112000158 |
News Archive
Government officials, Lobbyists and other Health Care advocates from Washington D.C. will land in Cleveland to explain to Northeast Ohio's businesses and employers the status of and potential implications from Health Care reform.
Cancer Research UK, Cancer Research Technology (CRT) - the charity's development and commercialisation arm - and Astex Therapeutics Limited announced today that they have agreed to take into development a potential new anti-cancer treatment.
An emerging technique designed to quickly distinguish between people with active and dormant tuberculosis may help health professionals diagnose the disease sooner, thereby potentially limiting early exposure to the disease, according to a study conducted by researchers at Duke University Medical Center.
Impax Laboratories, Inc. today announced the execution of a definitive agreement under which Impax will acquire Tower Holdings, Inc., including operating subsidiaries CorePharma LLC and Amedra Pharmaceuticals LLC, and Lineage Therapeutics Inc. (together, the "Companies") for $700 million in cash, subject to certain customary purchase price adjustments.
The bacterium that causes Legionnaires' disease remains difficult to track. French researchers have now developed a new technique that should allow living representatives of this dangerous pathogen to be detected much more quickly than with conventional methods. As they report in the journal Angewandte Chemie, samples are exposed to an azide-modified compound that the pathogen specifically incorporates into its shell, which is made of saccharide units. A fluorescent marker attached to the azide groups is used to identify the pathogen.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Salima Isabelle Hassanaly, MD, FRCSC 330 Brookline Ave, Boston, MA 02215-5491 Ph: () - | Dr Salima Isabelle Hassanaly, MD, FRCSC 330 Brookline Ave, Boston, MA 02215-5400 Ph: (617) 667-3391 |
News Archive
Government officials, Lobbyists and other Health Care advocates from Washington D.C. will land in Cleveland to explain to Northeast Ohio's businesses and employers the status of and potential implications from Health Care reform.
Cancer Research UK, Cancer Research Technology (CRT) - the charity's development and commercialisation arm - and Astex Therapeutics Limited announced today that they have agreed to take into development a potential new anti-cancer treatment.
An emerging technique designed to quickly distinguish between people with active and dormant tuberculosis may help health professionals diagnose the disease sooner, thereby potentially limiting early exposure to the disease, according to a study conducted by researchers at Duke University Medical Center.
Impax Laboratories, Inc. today announced the execution of a definitive agreement under which Impax will acquire Tower Holdings, Inc., including operating subsidiaries CorePharma LLC and Amedra Pharmaceuticals LLC, and Lineage Therapeutics Inc. (together, the "Companies") for $700 million in cash, subject to certain customary purchase price adjustments.
The bacterium that causes Legionnaires' disease remains difficult to track. French researchers have now developed a new technique that should allow living representatives of this dangerous pathogen to be detected much more quickly than with conventional methods. As they report in the journal Angewandte Chemie, samples are exposed to an azide-modified compound that the pathogen specifically incorporates into its shell, which is made of saccharide units. A fluorescent marker attached to the azide groups is used to identify the pathogen.
› Verified 5 days ago
Dr. Maan Sulaiman A Alkharashi, M.D. Ophthalmology Medicare: Medicare Enrolled Practice Location: 300 Longwood Ave, Fegan 4, Boston, MA 02115 Phone: 857-523-6040 | |
Daniel J Townsend, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 175 Cambridge St, C/o Prooptical, Boston, MA 02114 Phone: 617-723-3937 Fax: 617-523-5006 | |
Daniel Robert Lefebvre, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 243 Charles St, 10th Floor -- Ophthalmic Plastic Surgery, Boston, MA 02114 Phone: 617-523-7900 | |
Dr. Seanna Rae Grob, MD, MAS Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 243 Charles St, Boston, MA 02114 Phone: 617-523-7900 | |
Ravi Parikh, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 243 Charles St, Boston, MA 02114 Phone: 617-573-3288 | |
Michael V Boland, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 243 Charles St, Boston, MA 02114 Phone: 617-573-3611 | |
Dr. Parvathy A Pillai, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 243 Charles St, Boston, MA 02114 Phone: 617-647-1226 Fax: 617-573-3181 |